Table 3.
Distribution of TAS2R genetic variants and their association with risk for papillary thyroid carcinoma.
| Controls (%) | Case (%) | Odds ratio (95% CI)a | P | |
|---|---|---|---|---|
| TAS2R3/4 diplotype | ||||
| TC/TC | 229 (44.6) | 121 (48.4) | 1.00 (Reference) | |
| TC/CG | 170 (33.1) | 84 (33.6) | 0.89 (0.64–1.27) | 0.549 |
| CC/TC | 63 (12.3) | 14 (5.60) | 0.43 (0.23–0.79) | 0.007 |
| CG/CG | 35 (6.82) | 21 (8.40) | 1.07 (0.59–1.94) | 0.822 |
| CC/CG | 14 (2.73) | 10 (4.00) | — | |
| CC/CC | 2 (0.39) | — | — | |
| */* | 434 (84.6) | 226 (90.4) | 1.00 (Reference) | |
| CC/* | 49 (15.4) | 24 (9.60) | 0.59 (0.36–0.97) | 0.036 |
| TAS2R38 diplotype | ||||
| PAV/PAV | 171 (33.3) | 87 (34.8) | 1.00 (Reference) | |
| PAV/AVI | 252 (49.1) | 109 (43.6) | 0.82 (0.58–1.17) | 0.273 |
| AVI/AVI | 89 (17.4) | 54 (21.6) | 1.26 (0.82–1.95) | 0.289 |
| AVI/AAV | 1 (0.19) | — | ||
| TAS2R diplotype in chromosome 12 b | ||||
| TA/TA | 264 (51.7) | 128 (52.0) | 1.00 (Reference) | |
| CA/TA | 148 (28.9) | 69 (28.1) | 0.97 (0.68–1.41) | 0.938 |
| TA/TG | 48 (9.39) | 25 (10.2) | 1.09 (0.64–1.85) | 0.761 |
| CA/TG | 26 (5.09) | 10 (4.07) | 0.87 (0.40–1.89) | 0.733 |
| CA/CA | 21 (4.11) | 10 (4.07) | 0.88 (0.39–1.98) | 0.751 |
| CA/CG | 3 (0.59) | 1 (0.41) | — | — |
| CG/TG | 1 (0.20) | 1 (0.41) | — | — |
| CG/CG | — | 1 (0.41) | — | — |
| TG/TG | — | 1 (0.41) | — | — |
95% CI, 95% confidence interval. Subjects with diplotypes with a frequency below 3% were excluded from the logistic regression tests based on rarity. aThe odds ratio was adjusted for the family history of thyroid cancer. bSix individuals were excluded due to missing genotype data.